Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217-21. Erratum in: J Neurol Neurosurg Psychiatry 2001 Jun;70(6):821.
Bhakta BB, Tennant A, Cozens JA, et al Application of item response theory to measure the disabling effects of severe upper limb spasticity in stroke and the consequent carer burden. Cerebrovascular Dis 1999;9:124.
Brin MF Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997;6:S208-20. Review.
Dupre E Debilite mentale and debilite motrice associees. Rev Neurol 1910;20:54-56.
Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008 May;89(5):799-806. doi: 10.1016/j.apmr.2008.01.007.
Fox PJ, Kohatsu N, Max W, Arnsberger P Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040. J Public Health Policy. 2001;22(1):88-97.
Hobbelen JS, Koopmans RT, Verhey FR, Habraken KM, de Bie RA Diagnosing paratonia in the demented elderly: reliability and validity of the Paratonia Assessment Instrument (PAI). Int Psychogeriatr. 2008 Aug;20(4):840-52. doi: 10.1017/S1041610207006424. Epub 2008 Jan 7.
Hobbelen JS, Verhey FR, Bor JH, de Bie RA, Koopmans RT Passive movement therapy in patients with moderate to severe paratonia; study protocol of a randomised clinical trial (ISRCTN43069940). BMC Geriatr. 2007 Dec 19;7:30.
Kao I, Drachman DB, Price DL Botulinum toxin: mechanism of presynaptic blockade. Science. 1976 Sep 24;193(4259):1256-8.
Knapp M, Comas-Herrera, Somani A, Banerjee S Dementia: Summary report for the National Audit Office international comparisons. London: Personal Social Services Research Unit London School of Economics and Political Science and Section of Mental Health and Ageing The Institute of Psychiatry, King's College London; 2007.
Naumann M, Yakovleff A, Durif F; BOTOX Cervical Dystonia Prospective Study Group A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002 Jan;249(1):57-63.
Souren LE, Franssen EH, Reisberg B Neuromotor changes in Alzheimer's disease: implications for patient care. J Geriatr Psychiatry Neurol. 1997 Jul;10(3):93-8. Review.
Waardenburg H, Elvers W, Van Vechgel F, Oostendorp R Can paratonia be measured reliably? Evaluation of the reliability of a visual analogue scale and the modified tonus sclae of Ashworth for measuring paratonia. Nederlands Tijdschrift voor Fysiotherapie (in dutch) 1999;102:30-35.
Waltz CFSOL, Lenz ER Measurement in Nursing Research, 2nd ed. Philadelphia: F.A. Davis, 1991.
Warden V, Hurley AC, Volicer L Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003 Jan-Feb;4(1):9-15.
Wells DL, Dawson P, Sidani S, Craig D, Pringle D Effects of an abilities-focused program of morning care on residents who have dementia and on caregivers. J Am Geriatr Soc. 2000 Apr;48(4):442-9.
A Randomized, Placebo Controlled Trial of Botulinum Toxin for Paratonic Rigidity in People With Advanced Cognitive Impairment
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
